Revolution Medicines Stock Analysis

RVMD Stock  USD 38.20  1.14  2.90%   
Revolution Medicines is undervalued with Real Value of 47.35 and Target Price of 73.43. The main objective of Revolution Medicines stock analysis is to determine its intrinsic value, which is an estimate of what Revolution Medicines is worth, separate from its market price. There are two main types of Revolution Medicines' stock analysis: fundamental analysis and technical analysis.
The Revolution Medicines stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Revolution Medicines' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.

Revolution Stock Analysis Notes

About 98.0% of the company shares are owned by institutional investors. The book value of Revolution Medicines was at this time reported as 12.19. The company recorded a loss per share of 3.58. Revolution Medicines had not issued any dividends in recent years. Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Revolution Medicines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 212 people. To find out more about Revolution Medicines contact Mark Goldsmith at 650 481 6801 or learn more at https://www.revmed.com.

Revolution Medicines Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Revolution Medicines' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Revolution Medicines or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Revolution Medicines generated a negative expected return over the last 90 days
Net Loss for the year was (600.09 M) with loss before overhead, payroll, taxes, and interest of (592.23 M).
Revolution Medicines currently holds about 461.43 M in cash with (557.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.26.
Revolution Medicines has a poor financial position based on the latest SEC disclosures
Over 98.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Disposition of 2041 shares by Cislini Jeff of Revolution Medicines at 38.7105 subject to Rule 16b-3

Revolution Medicines Upcoming and Recent Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Revolution Largest EPS Surprises

Earnings surprises can significantly impact Revolution Medicines' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-02-28
2021-12-31-0.64-0.71-0.0710 
2023-05-08
2023-03-31-0.81-0.720.0911 
2021-11-10
2021-09-30-0.63-0.72-0.0914 
View All Earnings Estimates

Revolution Medicines Environmental, Social, and Governance (ESG) Scores

Revolution Medicines' ESG score is a quantitative measure that evaluates Revolution Medicines' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Revolution Medicines' operations that may have significant financial implications and affect Revolution Medicines' stock price as well as guide investors towards more socially responsible investments.

Revolution Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Bellevue Group Ag2024-12-31
4.4 M
Boxer Capital Management, Llc2024-12-31
4.3 M
Boxer Capital Llc2024-09-30
4.3 M
Bvf Inc2024-12-31
4.2 M
Alphabet Inc2024-12-31
4.1 M
Geode Capital Management, Llc2024-12-31
4.1 M
Woodline Partners Lp2024-12-31
3.9 M
Jpmorgan Chase & Co2024-12-31
3.8 M
Casdin Capital, Llc2024-12-31
3.7 M
Vanguard Group Inc2024-12-31
17.1 M
Blackrock Inc2024-12-31
14.7 M
Note, although Revolution Medicines' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Revolution Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.31 B.

Revolution Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.24)(0.25)
Return On Capital Employed(0.29)(0.30)
Return On Assets(0.23)(0.25)
Return On Equity(0.26)(0.28)

Management Efficiency

Revolution Medicines has return on total asset (ROA) of (0.1866) % which means that it has lost $0.1866 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2933) %, meaning that it created substantial loss on money invested by shareholders. Revolution Medicines' management efficiency ratios could be used to measure how well Revolution Medicines manages its routine affairs as well as how well it operates its assets and liabilities. As of March 25, 2025, Return On Tangible Assets is expected to decline to -0.25. In addition to that, Return On Capital Employed is expected to decline to -0.3. At present, Revolution Medicines' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 18.4 M, whereas Other Assets are forecasted to decline to 1.09.
Last ReportedProjected for Next Year
Book Value Per Share 13.50  14.18 
Tangible Book Value Per Share 13.08  13.73 
Enterprise Value Over EBITDA(10.05)(10.55)
Price Book Value Ratio 3.24  3.08 
Enterprise Value Multiple(10.05)(10.55)
Price Fair Value 3.24  3.08 
Enterprise Value6.9 B7.3 B
Revolution Medicines has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta
1.457
Return On Assets
(0.19)
Return On Equity
(0.29)

Technical Drivers

As of the 25th of March, Revolution Medicines holds the Variance of 6.16, risk adjusted performance of (0.05), and Coefficient Of Variation of (1,521). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Revolution Medicines, as well as the relationship between them. Please check Revolution Medicines standard deviation, as well as the relationship between the maximum drawdown and kurtosis to decide if Revolution Medicines is priced some-what accurately, providing market reflects its current price of 38.2 per share. Given that Revolution Medicines has information ratio of (0.06), we recommend you to check out Revolution Medicines's recent market performance to make sure the company can sustain itself at a future point.

Revolution Medicines Price Movement Analysis

Execute Study
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Revolution Medicines middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Revolution Medicines. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Revolution Medicines Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Revolution Medicines insiders, such as employees or executives, is commonly permitted as long as it does not rely on Revolution Medicines' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Revolution Medicines insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Cislini Jeff few days ago
Disposition of 2041 shares by Cislini Jeff of Revolution Medicines at 38.7105 subject to Rule 16b-3
 
Xiaolin Wang over a week ago
Disposition of 2718 shares by Xiaolin Wang of Revolution Medicines subject to Rule 16b-3
 
Horn Margaret A over two weeks ago
Disposition of 4331 shares by Horn Margaret A of Revolution Medicines at 44.1853 subject to Rule 16b-3
 
Mark Goldsmith over two weeks ago
Acquisition by Mark Goldsmith of 97400 shares of Revolution Medicines subject to Rule 16b-3
 
Kelsey Stephen Michael over two weeks ago
Disposition of 4665 shares by Kelsey Stephen Michael of Revolution Medicines at 44.1853 subject to Rule 16b-3
 
Horn Margaret A over two weeks ago
Acquisition by Horn Margaret A of 28600 shares of Revolution Medicines subject to Rule 16b-3
 
Mark Goldsmith over three weeks ago
Acquisition by Mark Goldsmith of 341100 shares of Revolution Medicines at 40.74 subject to Rule 16b-3
 
Cislini Jeff over two months ago
Disposition of 2406 shares by Cislini Jeff of Revolution Medicines at 40.5 subject to Rule 16b-3
 
Mark Goldsmith over two months ago
Disposition of 50900 shares by Mark Goldsmith of Revolution Medicines at 4.09 subject to Rule 16b-3
 
Mark Goldsmith over three months ago
Disposition of 36600 shares by Mark Goldsmith of Revolution Medicines at 0.49 subject to Rule 16b-3
 
Mark Goldsmith over three months ago
Disposition of 5000 shares by Mark Goldsmith of Revolution Medicines at 55.0268 subject to Rule 16b-3
 
Patel Sushil over three months ago
Disposition of 5000 shares by Patel Sushil of Revolution Medicines at 24.84 subject to Rule 16b-3

Revolution Medicines Outstanding Bonds

Revolution Medicines issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Revolution Medicines uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Revolution bonds can be classified according to their maturity, which is the date when Revolution Medicines has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Revolution Medicines Predictive Daily Indicators

Revolution Medicines intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Revolution Medicines stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Revolution Medicines Corporate Filings

F4
24th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
19th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
4th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
26th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
14th of February 2025
Other Reports
ViewVerify
F4
22nd of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
20th of December 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
18th of December 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify

Revolution Medicines Forecast Models

Revolution Medicines' time-series forecasting models are one of many Revolution Medicines' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Revolution Medicines' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Revolution Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Revolution Medicines prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Revolution shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Revolution Medicines. By using and applying Revolution Stock analysis, traders can create a robust methodology for identifying Revolution entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(43.69)(41.50)
Operating Profit Margin(48.38)(45.96)
Net Loss(43.34)(41.17)
Gross Profit Margin 0.65  0.69 

Current Revolution Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Revolution analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Revolution analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
73.43Strong Buy15Odds
Revolution Medicines current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Revolution analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Revolution stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Revolution Medicines, talking to its executives and customers, or listening to Revolution conference calls.
Revolution Analyst Advice Details

Revolution Stock Analysis Indicators

Revolution Medicines stock analysis indicators help investors evaluate how Revolution Medicines stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Revolution Medicines shares will generate the highest return on investment. By understating and applying Revolution Medicines stock analysis, traders can identify Revolution Medicines position entry and exit signals to maximize returns.
Begin Period Cash Flow699.2 M
Common Stock Shares Outstanding167.7 M
Total Stockholder Equity2.3 B
Tax Provision-753 K
Property Plant And Equipment Net141.8 M
Cash And Short Term Investments2.3 B
Cash543.1 M
Accounts Payable54.4 M
Net Debt-407.2 M
50 Day M A40.5558
Total Current Liabilities163.9 M
Non Current Assets Total230.7 M
Non Currrent Assets Other17.6 M
Stock Based Compensation79.2 M

Complementary Tools for Revolution Stock analysis

When running Revolution Medicines' price analysis, check to measure Revolution Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines is operating at the current time. Most of Revolution Medicines' value examination focuses on studying past and present price action to predict the probability of Revolution Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines' price. Additionally, you may evaluate how the addition of Revolution Medicines to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.